Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Psychometric Analyses to Inform Item Reduction and Evaluate Sensitivity of the Early Mobility Impairment Questionnaire for Multiple Sclerosis.
Health Care Resource Use and Cost Of Multiple Sclerosis in Slovakia: Results from the National Cross-Sectional Study.
Do evoked potentials contribute to the functional follow-up and clinical prognosis of multiple sclerosis?
Newly Identified Gait Patterns in Patient With Multiple Sclerosis May Be Related to Push-Off Quality.
NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.
Cross-disease transcriptomics: Unique IL-17A signaling in psoriasis lesions and an autoimmune PBMC signature.
Modelling the Impact of Persistence Improvements with an Electronic Injection Device on Escalation to 2nd Line Treatment in Patients with Relapsing Remitting Multiple Sclerosis (RRMS).
Olfactory dysfunction in patients with multiple sclerosis.
A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
Evaluation of Disability Progression as an Endpoint in Clinical Trials for Relapsing-Remitting Multiple Sclerosis (RRMS): Comparison of the Define and Confirm Studies.
Astrocyte tissue factor controls CNS hemostasis and autoimmune inflammation.
Susac's syndrome: Leptomeningeal enhancement on 3D FLAIR MRI.
Histamine and Immune Biomarkers in CNS Disorders.
Cortical functional modifications following optic neuritis.
A Real-World Assessment of Annual Multiple Sclerosis Prevalence and Disease-Modifying Drug Treatment Rates Using an Administrative Claims Database.
Pharmacoeconomic Aspects of Multiple Sclerosis Treatments in Iran.
The Indirect Costs of Multiple Sclerosis Associated With Absenteeism In Poland.
Cost-Effectiveness of Subcutaneous Interferon Beta-1A in a Sub-Population of Multiple Sclerosis Patients (Kurtzke Expanded Disability Status Scale [EDSS]: >3.5-5.0).
Best Practices and Key Challenges in Cost-Effectiveness Modelling of Multiple Sclerosis Therapies.
Quality of Life Among Patients with Multiple Sclerosis Treated with Prolonged-Release Fampridine 10 Mg Tablets for Walking Impairment.
Sunshine, Sea, and Season of Birth: MS Incidence in Wales.
Pediatric Optic Neuritis Prospective Outcomes Study.
Further Understanding of the Immunopathology of Multiple Sclerosis: Impact on Future Treatments.
Biotinidase deficiency mimicking neuromyelitis optica beginning at the age of 4: A treatable disease.
Extra-Gastrointestinal Manifestations of Inflammatory Bowel Disease May Be Less Common Than Previously Reported.

Pages